

Special Issue

Kinase Inhibitors for Anticancer Therapies

Message from the Guest Editor

Targeting kinase pathways has emerged as a promising strategy in the fight against infectious diseases that are caused by pathogenic microbes such as bacteria, viruses, parasites, or fungi. Currently, several protein kinases are being successfully targeted for cancer treatment. The discovery of the roles of additional protein kinase targets has invigorated research for the development of new potential drugs as protein kinase inhibitors to combat cancer. This Special Issue entitled “Kinase Inhibitors for Anticancer Therapies” will showcase the recent trends in the field of drug discovery of kinase inhibitors, especially for anticancer therapy. In addition, review articles, research articles, and short communications will highlight the efforts of medicinal chemists to propose new molecules endowed with kinase inhibition properties and the strategies to enhance the activity profile of the existing pipeline.

Guest Editor

Dr. Jayalakshmi Sridhar

Department of Chemistry, College of Arts and Sciences, Xavier University of Louisiana, New Orleans, LA 70125, USA

Deadline for manuscript submissions

closed (31 October 2024)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/202966

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to molecular chemistry, now in its 29th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts, and novel materials. Pushing the boundaries of the discipline, we invite papers on all major fields of molecular chemistry and multidisciplinary topics bridging chemistry with biology, physics, and materials science, as well as timely reviews and topical issues on cutting-edge fields in all of these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarInLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).